drugset / Trial / NCT00807794

A Safety Clinical Trial of Different Doses of MEDI-507 in the Prevention of Acute Renal Allograft Rejection

NCT00807794

Phase 1 Completed 13 enrolled MedImmune LLC
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To evaluate the clinical safety of different doses of MEDI-507 through day 33.

Timeline

Start
1997-02
Primary completion
1997-11
Completion
1998-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Siplizumab Monoclonal antibody 0.012 mg/kg
Subject Siplizumab Monoclonal antibody 0.06 mg/kg
Subject Siplizumab Monoclonal antibody 0.12 mg/kg
Subject Siplizumab Monoclonal antibody 0.24 mg/kg
Subject Siplizumab Monoclonal antibody 0.5 mg/kg

Indications